BioSpace

Merck barred from making subcutaneous Keytruda in 8 European countries

With the patent court siding with Halozyme, Merck faces restrictions on a product that won approval in Europe last year.

By BioSpace

1 min read
Merck barred from making subcutaneous Keytruda in 8 European countries
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights